Literature DB >> 20978550

Understanding combination therapy with biologics and immunosuppressives for the treatment of Crohn's disease.

Jean-Frederic Colombel1.   

Abstract

Entities:  

Year:  2010        PMID： 20978550      PMCID： PMC2950663     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

2.  Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.

Authors:  Harry Sokol; Philippe Seksik; Fabrice Carrat; Isabelle Nion-Larmurier; Ariane Vienne; Laurent Beaugerie; Jacques Cosnes
Journal:  Gut       Date:  2010-06-29       Impact factor: 23.059

3.  Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.

Authors:  G R Lichtenstein; R H Diamond; C L Wagner; A A Fasanmade; A D Olson; C W Marano; J Johanns; Y Lang; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2009-04-21       Impact factor: 8.171

4.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682
  4 in total
  4 in total

1.  When should combination therapy for patients with Crohn's disease be discontinued?

Authors:  Jean-Frédéric Colombel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-04

Review 2.  Use of thiopurines in inflammatory bowel disease: Safety issues.

Authors:  Anastasia Konidari; Wael El Matary
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

3.  Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting.

Authors:  Joshua C Berkowitz; Joanna Stein-Fishbein; Sundas Khan; Richard Furie; Keith S Sultan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2018-02-06

Review 4.  Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.

Authors:  Ray K Boyapati; Joana Torres; Carolina Palmela; Claire E Parker; Orli M Silverberg; Sonam D Upadhyaya; Tran M Nguyen; Jean-Frédéric Colombel
Journal:  Cochrane Database Syst Rev       Date:  2018-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.